Systematic review and meta‐analysis of reported adverse events of long‐term intranasal oxytocin treatment for autism spectrum disorder

Cai, Qizheng; Feng, Lei; Yap, Kai Zhen

doi:10.1111/pcn.12627

Cited by 63 publications

(28 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We did not observe any significant differences in aversive events between the two OT and placebo arms ([60]; see also Table 2 in Cai et al [71]).…”

Section: Assessment Of Harm: Epilepsymentioning

confidence: 83%

“…In addition, epilepsy is likely found in 46% of ASD patients with low IQ [70]. Because these subjects have rarely been subjects in the many recent biological and clinical studies [46,47,48,49,71], we must consider this important proportion of individuals with the so-called Kanner type of ASD [5]. Therefore, we investigated the potential therapeutic and adverse effects of intranasal OT administration, especially in adolescents and adults with ASD and comorbid intellectual disability, with regard to core symptoms of social deficits.…”

Section: Asd With Comorbiditiesmentioning

confidence: 99%

See 1 more Smart Citation

Social Interaction Improved by Oxytocin in the Subclass of Autism with Comorbid Intellectual Disabilities

et al. 2019

View full text Add to dashboard Cite

Approximately half of all autism spectrum disorder (ASD) individuals suffer from comorbid intellectual disabilities. Furthermore, the prevalence of epilepsy has been estimated to be 46% of patients with low intelligence quotient. It is important to investigate the therapeutic benefits and adverse effects of any recently developed drugs for this proportion of individuals with the so-called Kanner type of ASD. Therefore, we investigated the therapeutic and/or adverse effects of intranasal oxytocin (OT) administration, especially in adolescents and adults with ASD and comorbid intellectual disability and epilepsy, with regard to core symptoms of social deficits. We have already reported three randomized placebo-controlled trials (RCTs). However, we revisit results in our pilot studies from the view of comorbidity. Most of the intellectually disabled participants were found to be feasible participants of the RCT. We observed significantly more events regarded as reciprocal social interaction in the OT group compared with the placebo group. In the trial, no or little differences in adverse events were found between the OT and placebo arms, as found in some other reports. However, seizures were induced in three participants with medical history of epilepsy during or after OT treatment. In conclusion, we stress that behavioral changes in ASD patients with intellectual disabilities could be recognized not by the conventional measurements of ASD symptoms but by detailed evaluation of social interactions arising in daily-life situations.

show abstract

“…We did not observe any significant differences in aversive events between the two OT and placebo arms ([60]; see also Table 2 in Cai et al [71]).…”

Section: Assessment Of Harm: Epilepsymentioning

confidence: 83%

Section: Asd With Comorbiditiesmentioning

confidence: 99%

Social Interaction Improved by Oxytocin in the Subclass of Autism with Comorbid Intellectual Disabilities

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Although most other fields would consider adverse effects in any intervention (medical, social-behavioral, other), autism research rarely describes adverse events with the exception of pharmacological research involving children (e.g. Cai et al, 2018).…”

Section: Outcomementioning

confidence: 99%

Listening to the autistic voice: Mental health priorities to guide research and practice in autism from a stakeholder-driven project

Benevides

Shore

Palmer³

et al. 2020

Autism

147

View full text Add to dashboard Cite

Autistic adults are significantly more likely to experience co-occurring mental health conditions such as depression and anxiety. Although intervention studies are beginning to be implemented with autistic adults to address mental health outcomes, little is known about what research autistic adults feel is needed, or what mental health outcomes are of value to them. The purpose of this article is to describe a project that involved more than 350 autistic adults and other stakeholders as coproducers of research priorities on mental health. Through a variety of methods including a large online survey, two large stakeholder meetings, and three face-to-face focus groups, the project team identified five top priorities for mental health research which should be incorporated by researchers and practitioners in their work with autistic adults. These included research to inform trauma-informed care approaches; societal approaches for inclusion and acceptance of autistic individuals; community-available approaches for self-management of mental health; evaluation of adverse mental health outcomes of existing interventions; and improvements in measurement of quality of life, social well-being, and other preferred outcomes in autistic adults. Lay Abstract Autistic adults commonly experience mental health conditions. However, research rarely involves autistic adults in deciding priorities for research on mental healthcare approaches that might work for them. The purpose of this article is to describe a stakeholder-driven project that involved autistic adults in co-leading and designing research about priorities to address mental health needs. Through a large online survey, two large meetings, and three face-to-face focus group discussions involving over 350 stakeholders, we identified five priorities for mental health research desired by autistic adults. These priorities and preferred outcomes should be used to guide research and practice for autistic adults.

show abstract

“…Further, several meta-analysis have characterized the side-effect profile of single dose and longterm i.n. OXT and the results support OXT as well tolerated and safe, side-effects not differing between OXT and placebo (69,70). However, safety should be further evaluated including larger groups, and focusing on sex, age, dosing, and treatment course and also studying putative side-effect that might occur longtime after treatment.…”

Section: Safetymentioning

confidence: 78%

Oxytocin as Treatment for Social Cognition, Not There Yet

Erdozain¹,

Peñagarikano²

2020

Front. Psychiatry

View full text Add to dashboard Cite

In a short time, oxytocin has progressed from being a regular hormone involved in parturition and breastfeeding to be possibly the neuromodulator that has gathered the most attention. Attributed many positive roles in the modulation of different aspects of social behavior, such as bonding, empathy, cooperation, trust, and generosity, as well as roles as a natural anxiolytic and antidepressant, the expectations on oxytocin becoming a treatment for a number of disorders with associated social deficits have dramatically raised over the last years. However, despite the field has been investigating oxytocin's role in social behavior for over twenty years, there are still many unknowns on oxytocin's mechanisms of action and efficiency and the increasing number of clinical trials administering oxytocin to different clinical groups seem to disagree in its properties and report in most cases conflicting results. This has led to some disappointment among researchers and clinicians as oxytocin might not be the miraculous molecule that works in a "one size fits all" fashion initially considered. Conversely, this down-side of oxytocin might merely reflect the complexity of its neurotransmission system. The current reality is that, although oxytocin seems to have potential therapeutic value, there are key questions that remain unanswered as to decide the optimal target groups and treatment course. Here, we present an overview on critical points regarding the oxytocin system in health and disease that need to be better understood to establish its therapeutic properties and to decide who could benefit the most from its treatment.

show abstract

Systematic review and meta‐analysis of reported adverse events of long‐term intranasal oxytocin treatment for autism spectrum disorder

Cited by 63 publications

References 75 publications

Social Interaction Improved by Oxytocin in the Subclass of Autism with Comorbid Intellectual Disabilities

Social Interaction Improved by Oxytocin in the Subclass of Autism with Comorbid Intellectual Disabilities

Listening to the autistic voice: Mental health priorities to guide research and practice in autism from a stakeholder-driven project

Oxytocin as Treatment for Social Cognition, Not There Yet

Contact Info

Product

Resources

About